Upgrade to SI Premium - Free Trial

Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX) Following Data

June 1, 2026 9:59 AM
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $30.00 price target on Immuneering Corporation (NASDAQ: IMRX) after the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles